Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

4,804 studies for “AstraZeneca”

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)Active Not Recruiting
NCT05925803Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Systemic Sclerosis · Scleroderma
United States, Austria, Belgium, Canada, China +18 more
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruiting
NCT04169737Phase 2Updated Sep 10, 2026
Sponsor: M.D. Anderson Cancer Center
Recurrent Chronic Lymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma · Refractory Chronic Lymphocytic Leukemia · Refractory Small Lymphocytic Lymphoma
United States
A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954Not Yet Recruiting
NCT07812077Phase 1Updated Sep 10, 2026
Sponsor: AstraZeneca
Healthy Participants
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruiting
NCT06897930Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
United States, Australia, Canada, United Kingdom
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.Recruiting
NCT07619131Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Hypercholesterolaemia
United States, Bulgaria, Canada, Denmark, Germany +6 more
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruiting
NCT05835310Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States, Argentina, Brazil, Canada, China +12 more
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive Not Recruiting
NCT04493853Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Hormone-Sensitive Prostate Cancer
United States, Argentina, Australia, Austria, Belgium +27 more
Fasenra Pediatric Japan Post-Marketing Study(PMS)Active Not Recruiting
NCT06427876N/AUpdated Sep 10, 2026
Sponsor: AstraZeneca
Bronchial Asthma
Japan
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal AntibodyRecruiting
NCT07285213Phase 2Updated Sep 10, 2026
Sponsor: AstraZeneca
Clostridioides Difficile Infection
United States, Australia, Canada, Denmark, France +9 more
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusRecruiting
NCT07776509Phase 3Updated Sep 10, 2026
Sponsor: AstraZeneca
Obesity or Overweight · Weight-Related Comorbidity · With/Without Diabetes Mellitus, Type 2
United States, Argentina, Brazil, Canada, China +6 more
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMRecruiting
NCT07667803Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Weight Management
United States, Argentina, Australia, Brazil, Canada +14 more
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerActive Not Recruiting
NCT04590963Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
United States, Argentina, Australia, Austria, Belgium +18 more
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive Not Recruiting
NCT05941897Phase 2Updated Sep 9, 2026
Sponsor: AstraZeneca
Advanced or Metastatic NSCLC
Russia
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruiting
NCT07343960Phase 1Updated Sep 9, 2026
Sponsor: AstraZeneca
Moderate Hepatic Impairment
United States
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR AmyloidosisRecruiting
NCT06355934N/AUpdated Sep 9, 2026
Sponsor: AstraZeneca
ATTR Amyloidosis
United States, Canada, China, Denmark, Germany +6 more
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With AsthmaRecruiting
NCT06471257Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Asthma
China, Hong Kong
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung CancerActive Not Recruiting
NCT04351555Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Austria, Brazil, Bulgaria, Canada +20 more
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesRecruiting
NCT03549754N/AUpdated Sep 9, 2026
Sponsor: AstraZeneca
Type 2 Diabetes · Hypertension · Chronic Kidney Disease · Heart Failure
Brazil, Chile, Costa Rica, Côte d’Ivoire, Egypt +15 more
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in BelarusRecruiting
NCT07288515N/AUpdated Sep 9, 2026
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
Belarus
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerActive Not Recruiting
NCT02962063Phase 1, Phase 2Updated Sep 9, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Esophageal Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
United States
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruiting
NCT07662213Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus
United States, Argentina, Australia, Brazil, Bulgaria +10 more
Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseActive Not Recruiting
NCT06450197Phase 2Updated Sep 9, 2026
Sponsor: AstraZeneca
Moderate to Severe Crohn's Disease
United States, Argentina, Australia, Belgium, Brazil +21 more
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerRecruiting
NCT07529717Phase 1, Phase 2Updated Sep 9, 2026
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Australia, South Korea
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.Recruiting
NCT07753993Phase 3Updated Sep 9, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease
United States, Argentina, Australia, Brazil, Bulgaria +32 more
Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) DiseaseActive Not Recruiting
NCT06851806NAUpdated Sep 9, 2026
Sponsor: AstraZeneca
Respiratory Syncytial Virus (RSV)
India

4,804 studies found